1. Executive Summary
1.1.Regional Market Share
1.2. Business Trends
1.3.Opioid Use Disorder (OUD) Market: COVID-19 Outbreak
1.4.Regional Trends
1.5. Segmentation Snapshot
2. Research Methodology
2.1. Research Objective
2.2.Research Approach
2.3.Data Sourcing and Methodology
2.4. Primary Research
2.5. Secondary Research
2.5.1. Paid Sources
2.5.2.Public Sources
2.6.Market Size Estimation and Data Triangulation
3. Market Characteristics
3.1. Market Definition
3.2.Opioid Use Disorder (OUD) Market: COVID-19 Impact
3.3.Key Segmentations
3.4. Key Developments
3.5. Allied Industry Data
4. Opioid Use Disorder (OUD) Market – Industry Insights
4.1.Industry Segmentation
4.2. COVID-19 overview of world economy
4.3. Industry Ecosystem Channel Analysis
4.4. Innovation & Sustainability
5. Macroeconomic Indicators
6. Recent Developments
7.Market Dynamics
7.1. Introduction
7.2.Growth Drivers
7.3.Market Opportunities
7.4. Market Restraints
7.5.Market Trends
8. Risk Analysis
9. Market Analysis
9.1. Porter's Five Forces
9.2.PEST Analysis
9.2.1. Political
9.2.2.Economic
9.2.3.Social
9.2.4.Technological
10. Opioid Use Disorder (OUD) Market
10.1.Overview
10.2. Historical Analysis (2019-2022)
10.2.1. Market Size, Y-o-Y Growth (%) and Market Forecast
11.Opioid Use Disorder (OUD) Market Size & Forecast 2024A-2034F
11.1.Overview
11.2. Key Findings
11.3. Market Segmentation
11.3.1.By Drug Class
11.3.1.1. Buprenorphine
11.3.1.1.1. By Value (USD Million) 2024-2034F
11.3.1.1.2.Market Share (%) 2024-2034F
11.3.1.1.3.Y-o-Y Growth (%) 2024-2034F
11.3.1.2.Methadone
11.3.1.2.1.By Value (USD Million) 2024-2034F
11.3.1.2.2. Market Share (%) 2024-2034F
11.3.1.2.3. Y-o-Y Growth (%) 2024-2034F
11.3.1.3.Naltrexone
11.3.1.3.1.By Value (USD Million) 2024-2034F
11.3.1.3.2. Market Share (%) 2024-2034F
11.3.1.3.3. Y-o-Y Growth (%) 2024-2034F
11.3.2. By Route of Administration
11.3.2.1.Oral
11.3.2.1.1.By Value (USD Million) 2024-2034F
11.3.2.1.2. Market Share (%) 2024-2034F
11.3.2.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.2.2. Sublingual
11.3.2.2.1. By Value (USD Million) 2024-2034F
11.3.2.2.2.Market Share (%) 2024-2034F
11.3.2.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.2.3. Intravenous
11.3.2.3.1. By Value (USD Million) 2024-2034F
11.3.2.3.2.Market Share (%) 2024-2034F
11.3.2.3.3.Y-o-Y Growth (%) 2024-2034F
11.3.3. By Distribution Channels
11.3.3.1.Hospitals Pharmacies
11.3.3.1.1.By Value (USD Million) 2024-2034F
11.3.3.1.2. Market Share (%) 2024-2034F
11.3.3.1.3. Y-o-Y Growth (%) 2024-2034F
11.3.3.2. Retail Pharmacies
11.3.3.2.1. By Value (USD Million) 2024-2034F
11.3.3.2.2.Market Share (%) 2024-2034F
11.3.3.2.3.Y-o-Y Growth (%) 2024-2034F
11.3.3.3. Online Pharmacies
11.3.3.3.1. By Value (USD Million) 2024-2034F
11.3.3.3.2.Market Share (%) 2024-2034F
11.3.3.3.3.Y-o-Y Growth (%) 2024-2034F
12. North America Opioid Use Disorder (OUD) Market Size & Forecast 2024A-2034F
12.1. Overview
12.2. Key Findings
12.3. Market Segmentation
12.3.1. By Drug Class
12.3.2.By Route of Administration
12.3.3.By Distribution Channels
12.4. Country
12.4.1. United States
12.4.2.Canada
13. Europe Opioid Use Disorder (OUD) Market Size & Forecast 2024A-2034F
13.1. Overview
13.2. Key Findings
13.3. Market Segmentation
13.3.1. By Drug Class
13.3.2.By Route of Administration
13.3.3.By Distribution Channels
13.4. Country
13.4.1.Germany
13.4.2.United Kingdom
13.4.3.France
13.4.4. Italy
13.4.5.Spain
13.4.6.Russia
13.4.7.Rest of Europe (BENELUX, NORDIC, Hungary, Turkey & Poland)
14. Asia-Pacific Opioid Use Disorder (OUD) Market Size & Forecast 2024A-2034F
14.1.Overview
14.2. Key Findings
14.3. Market Segmentation
14.3.1. By Drug Class
14.3.2.By Route of Administration
14.3.3.By Distribution Channels
14.4. Country
14.4.1. India
14.4.2.China
14.4.3. South Korea
14.4.4. Japan
14.4.5. Rest of APAC
15. Middle East and Africa Opioid Use Disorder (OUD) Market Size & Forecast 2024A-2034F
15.1.Overview
15.2. Key Findings
15.3. Market Segmentation
15.3.1. By Drug Class
15.3.2.By Route of Administration
15.3.3.By Distribution Channels
15.4. Country
15.4.1. Israel
15.4.2.GCC
15.4.3.North Africa
15.4.4. South Africa
15.4.5.Rest of Middle East and Africa
16. Latin America Opioid Use Disorder (OUD) Market Size & Forecast 2024A-2034F
16.1. Overview
16.2. Key Findings
16.3. Market Segmentation
16.3.1. By Drug Class
16.3.2.By Route of Administration
16.3.3.By Distribution Channels
16.4. Country
16.4.1. Mexico
16.4.2.Brazil
16.4.3.Rest of Latin America
17. Competitive Landscape
17.1. Company market share, 2023
17.2.Key player overview
17.3. Key stakeholders
18. Company Profiles
18.1. Reckitt Benckiser Pharmaceuticals
18.1.1.Company Overview
18.1.2.Financial Overview
18.1.3.Key Product; Analysis
18.1.4.Company Assessment
18.1.4.1.Product Portfolio
18.1.4.2. Key Clients
18.1.4.3. Market Share
18.1.4.4. Recent News & Development (Last 3 Yrs.)
18.1.4.5. Executive Team
18.2.Johnson & Johnson
18.3.Purdue Pharma
18.4.Teva Pharmaceuticals
18.5.Mallinckrodt Pharmaceuticals
18.6.Indivior
18.7.Pfizer Inc.
18.8.GlaxoSmithKline plc
18.9.Alkermes plc
18.10.Titan Pharmaceuticals
18.11. Camurus AB
18.12.BioDelivery Sciences International, Inc.
18.13.Braeburn Inc.
18.14.Orexo AB
18.15.Insys Therapeutics
18.16.Other Prominent Players
19. Appendix
20.Consultant Recommendation
Select License Type
Our Clients
We have been working with some Fortune 500+ clients
.png){kind=icon}
